Features Partner Sites Information LinkXpress
Sign In
Demo Company

Overabundant Protein Kinase Found Connected to Chemotherapy-Resistant Cancer Cells

By BiotechDaily International staff writers
Posted on 06 Mar 2012
Print article
A molecular signaling pathway underlying the correlation of Aurora Kinase-A overexpression in human tumors with resistance to chemotherapy has been discovered.

In treatment-resistant cancers, this abnormally abundant protein kinase was found to prevent an important tumor-suppressor, p73, from entering the cell nucleus, where it would normally detect DNA damage and activate genes that force defective cells to undergo apoptosis. Like the better known p53, the tumor-suppressor p73 monitors DNA damage during cell division and orders apoptosis when it detects damage that cannot be repaired.

Inactivation of p53 is known to be common in many types of solid tumors. "The role of p73 in the maintenance of genomic stability has been better recognized in recent years and this tumor suppressor is believed to be functionally more important in cells that lack p53," said Subrata Sen, PhD, professor in the Department of Molecular Pathology at The University of Texas MD Anderson Cancer Center (Houston, TX, USA).

In a study reported in the February 14, 2012, issue of the journal Cancer Cell, senior author Sen and colleagues found that site-specific phosphorylation of p73 by Aurora Kinase-A (Aurora-A) leads to (a) loss of p73 ability to bind to DNA and to transactivate its target genes and (b) locking of p73 outside the nucleus, in the cell cytoplasm.

The chaperon protein Mortalin, which has been implicated in tumor formation and immortalization, was found to play a role in keeping Aurora-A phosphorylated p73 in the cytoplasm as well as in moving it out of the nucleus. Experiments in the study showed that lung, breast, and pancreatic cancer cells overexpressing Aurora-A have p73 evenly distributed in the nucleus and cytoplasm, but when treated with an Aurora-A inhibitor, p73 is found mainly in the nucleus. The team also analyzed 114 samples of human pancreatic ductal adenocarcinoma.

In addition, when lung cancer cells overexpressing Aurora-A were treated with cisplatin, cells with phosphorylated p73 were least sensitive to cell death caused by the chemotherapy. In the absence of Aurora-A overexpression, cells were more sensitive to cisplatin treatment.

In another aspect of the study, the investigators found that Aurora-A expressed at normal levels has a regular role to play in phosphorylating p73 in normal mitotic spindle assembly checkpoint function during cell division but that overabundant Aurora-A phosphorylation of p73 leads to dissociation, and thereby malfunction, of the spindle assembly checkpoint complex.

"Our discovery that Aurora A blocks the proper functioning of the tumor-suppressor p73 is a step toward understanding and addressing chemotherapy resistance with more effective treatment combinations," said Prof. Sen.

Related Links:
The University of Texas MD Anderson Cancer Center

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.